Medical Device Coverage: Do Private Payers Follow Medicare’s Lead?

Perspectives on Medical Reimbursement By JR Associates When making decisions about medical device coverage, do private insurers take their cues from Medicare (CMS)? Not necessarily, according to a recent study published in the peer-review journal, Health Affairs. According to the research abstract, an analysis of CMS national coverage decisions (NCDs) revealed that: ~50% were equivalent to corresponding private payer policies ~25% were…

Read More »

Reimbursement Strategy: Extending Product Reach Across Multiple Markets

How can medical technology innovators leverage reimbursement strategy across markets? Advice from JR Associates consultants

Perspectives on Medical Reimbursement By JR Associates When medical technology companies develop reimbursement strategies for the U.S. market, it’s a smart business move to look beyond this country’s borders. That’s the advice JR Associates VP of Global Health Policy, Jo Ellen Slurzberg shared in a recent interview with Medical Device Daily. Jo Ellen acknowledged that planning…

Read More »

Amyvid & Alzheimers Lesson: FDA Approval Is Not A Coverage Guarantee

Perspectives on Medical Reimbursement By JR Associates The path to advancements in disease detection and treatment is notoriously complex, circuitous and costly. However, even after FDA approval, there are no guarantees of reimbursement through CMS coverage. This is an essential lesson in the case of Eli Lilly’s Amyvid PET scan imaging agent, which is used…

Read More »